(NYSEMKT: PTHS) Pelthos Therapeutics's forecast annual revenue growth rate of 67.38% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.17%.
Pelthos Therapeutics's revenue in 2026 is $27,701,000.On average, 9 Wall Street analysts forecast PTHS's revenue for 2026 to be $226,261,014, with the lowest PTHS revenue forecast at $192,206,644, and the highest PTHS revenue forecast at $290,202,455. On average, 9 Wall Street analysts forecast PTHS's revenue for 2027 to be $393,686,309, with the lowest PTHS revenue forecast at $345,374,844, and the highest PTHS revenue forecast at $437,931,270.
In 2027, PTHS is forecast to generate $429,589,722 in revenue, with the lowest revenue forecast at $362,996,364 and the highest revenue forecast at $572,195,436.